Daewon Pharmaceutical Reports H1 Operating Profit of 4.4 Billion Won, Down 45.3% Due to Increased R&D and Marketing Expenses
Daewon Pharmaceutical announced on August 7 that its consolidated operating profit for the first half of this year was 4.4 billion won, a decrease of 45.3% compared to the same period last year. During the same period, sales increased by 3.1% to 310.9 billion won, and net profit for the period was reported at 5.7 billion won.
The company explained that profitability declined due to an increase in selling and administrative expenses, which was caused by research and development (R&D) costs for new drug development, as well as higher marketing expenses for the launch of new health functional foods.
Hot Picks Today
"Expensive, Smelly and Scary"... What's Happened to the "Honeymooners' Paradise" Tourists Have Abandoned?
- Women Who Say "A Husband's Annual Salary of 100 Million Won Is a Given"... Matchmaking CEO: "They Talk About It Like It's Nothing"
- "I Want to Eat Like Koreans..." Foreigners Who Once Opened Ramen Packs Now Keep Gochujang in Their Pantries
- Man in His 20s Detained for Killing Mother-in-Law, Abducting Wife... "Risk of Flight and Evidence Destruction"
- "They Said Today Was the Cheapest..." "Let's Get Wedding Jewelry!" Why Did the Luxury Brand Crowds Flocked To Cut Prices by 1.08 Million Won?
On the other hand, sales in the first half continued to grow, driven by increased prescriptions for products treating chronic diseases and strong sales of health functional foods.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
